Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy (Review)

  • Authors:
    • Yumeng Wei
    • Xinlin Pu
    • Ling Zhao
  • View Affiliations

  • Published online on: April 20, 2017     https://doi.org/10.3892/or.2017.5593
  • Pages: 3159-3166
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cancer is one of the most common causes of death and remains the first in China and the second in the US. The common treatments for cancer include surgery, radiation, chemotherapy, targeted therapy and immunotherapy, while chemotherapy remains one of the most important treatments. However, the efficacy of chemotherapy is limited due to drug induced-toxicities and resistance, particularly multiple drug resistance (MDR). Therefore, discovery and development of novel therapeutic drugs and/or combination therapy are urgently needed to reduce toxicity and improve efficacy. Paclitaxel has been widely used to treat various cancers including cervical, breast, ovarian, brain, bladder, prostate, liver and lung cancers. However, its therapeutic efficacy is limited and MDR is a major obstacle. Recently, numerous preclinical studies have shown that the combination of paclitaxel and curcumin may be an ideal strategy to reverse MDR and synergistically improve their therapeutic efficacy in cancer therapy. This review mainly focuses on the current development and progress of the combination of paclitaxel and curcumin in cancer therapy preclinically.
View Figures
View References

Related Articles

Journal Cover

June 2017
Volume 37 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wei, Y., Pu, X., & Zhao, L. (2017). Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy (Review). Oncology Reports, 37, 3159-3166. https://doi.org/10.3892/or.2017.5593
MLA
Wei, Y., Pu, X., Zhao, L."Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy (Review)". Oncology Reports 37.6 (2017): 3159-3166.
Chicago
Wei, Y., Pu, X., Zhao, L."Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy (Review)". Oncology Reports 37, no. 6 (2017): 3159-3166. https://doi.org/10.3892/or.2017.5593